Rate My Professor Michael Jenkinson

His research specializations include meningioma management encompassing incidental tumours, seizures, and quality of life; imaging and biology of brain metastases; and interventional clinical trials in neurosurgery and neuro-oncology. He has received grants from the MRC, Brain Tumour Charity, and NIHR. As chief investigator, he leads NIHR-funded trials including ROAM (Radiation versus Observation following surgical resection of Atypical Meningioma), STOP 'EM (Surgeons Trial of Prophylaxis for Epilepsy in Meningioma), SPRING (Seizure Prophylaxis in Glioma), and ReStart (Restarting DOAC after TBI), and is co-investigator on FUTURE GB and PROSSPER. He led the KEATING pilot study on ketogenic diets for glioblastoma patients and was co-chief investigator on the BASICS trial, which showed antibiotic-impregnated ventriculoperitoneal shunt catheters reduce infection rates from 6% to 2%, saving £135,000 per infection averted and establishing them as standard care in UK neurosurgery. Jenkinson holds leadership positions such as Vice President for Research, Impact and Innovation at the Society of British Neurological Surgeons, National Neurosurgery Specialty Lead for the Royal College of Surgeons of England, and Chair of the EORTC Meningioma Committee. In 2025, he received the Vilhelm Magnus Medal. Key publications include the EANO guideline on meningioma diagnosis and management (2021, Neuro-Oncology), BASICS trial results (2019), and a clinical tool for incidental meningioma management (2026, JAMA Oncology).